Physician

Sachin Gupta, M.D.

According to 2025 Medicare claims, Sachin Gupta, M.D. (NPI: 1144343005) practices hematology/oncology in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (NPI: 1083661607; TIN: 770324589) and primary practice location at 93720-3347.

Gupta's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 983 traditional Medicare patients, billed 532,837 HCPCS/CPT codes, and received $9,373,358 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 1,757 prescription claims across 257 beneficiaries totaling $4,942,693 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 64 claims. Open Payments data shows 56 records totaling $14,186. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $5,298,729 to $9,373,358. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,957,044 to $4,942,693. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $13,010 to $1,453.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	591	694,486	$5,298,729
2016	688	792,033	$6,085,303
2017	655	767,591	$6,230,414
2018	660	620,243	$5,321,512
2019	748	841,808	$7,572,153
2020	966	841,145	$10,759,391
2021	937	852,160	$11,435,496
2022	869	714,732	$8,959,364
2023	1,014	587,276	$7,439,279
2024	983	532,837	$9,373,358

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	229	2,215	$1,957,044
2016	242	2,130	$1,712,557
2017	271	2,593	$2,079,230
2018	301	2,541	$2,843,038
2019	344	2,913	$3,510,719
2020	346	3,310	$5,849,263
2021	284	2,626	$4,587,601
2022	275	2,287	$4,556,992
2023	293	2,156	$6,201,652
2024	257	1,757	$4,942,693

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	187	$31,958
2016	N/R	138	$28,259
2017	N/R	128	$25,693
2018	27	185	$38,969
2019	49	335	$87,099
2020	40	443	$121,458
2021	N/R	88	$5,782
2022	N/R	90	$3,832
2023	N/R	65	$12,230
2024	N/R	64	$50,080

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	542	1,898	$10
36415	Insertion of needle into vein for collection of blood sample	560	2,237	$9
83550	Iron binding capacity	489	1,059	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	557	2,592	$8
83540	Iron level	490	1,064	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	90	2,570	$1,238,079
Cabometyx	Cabozantinib S-Malate	28	840	$688,078
Ibrance	Palbociclib	29	812	$418,947
Jakafi	Ruxolitinib Phosphate	17	510	$279,341
Verzenio	Abemaciclib	17	476	$237,087

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$44,158
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	11	$4,285
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$827
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$547
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	56	$14,186	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sachin Gupta, M.D.?

Tedicare shows public-source Medicare data for Sachin Gupta, M.D. (NPI 1144343005), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sachin Gupta, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Sachin Gupta, M.D.?

Sachin Gupta, M.D. is linked to CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (billing NPI 1083661607) in the available physician profile data.

Does Sachin Gupta, M.D. have Open Payments data?

Sachin Gupta, M.D. has 56 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.